- Home
- KURA vs MLTX Comparison
KURA vs MLTX Comparison
Compare KURA & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KURA
- MLTX
- Stock Information
- Founded
- KURA 2014
- MLTX 2021
- Country
- KURA United States
- MLTX Switzerland
- Employees
- KURA N/A
- MLTX N/A
- Industry
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- KURA Health Care
- MLTX Health Care
- Exchange
- KURA Nasdaq
- MLTX Nasdaq
- Market Cap
- KURA 713.5M
- MLTX 595.6M
- IPO Year
- KURA N/A
- MLTX N/A
- Fundamental
- Price
- KURA $10.26
- MLTX $9.61
- Analyst Decision
- KURA Strong Buy
- MLTX Buy
- Analyst Count
- KURA 13
- MLTX 9
- Target Price
- KURA $25.00
- MLTX $37.63
- AVG Volume (30 Days)
- KURA 2.0M
- MLTX 6.2M
- Earning Date
- KURA 11-04-2025
- MLTX 11-07-2025
- Dividend Yield
- KURA N/A
- MLTX N/A
- EPS Growth
- KURA N/A
- MLTX N/A
- EPS
- KURA N/A
- MLTX N/A
- Revenue
- KURA $83,279,000.00
- MLTX N/A
- Revenue This Year
- KURA $68.63
- MLTX N/A
- Revenue Next Year
- KURA $141.59
- MLTX N/A
- P/E Ratio
- KURA N/A
- MLTX N/A
- Revenue Growth
- KURA N/A
- MLTX N/A
- 52 Week Low
- KURA $5.41
- MLTX $5.95
- 52 Week High
- KURA $19.73
- MLTX $62.75
- Technical
- Relative Strength Index (RSI)
- KURA 57.62
- MLTX 27.58
- Support Level
- KURA $9.08
- MLTX $8.92
- Resistance Level
- KURA $11.06
- MLTX $10.11
- Average True Range (ATR)
- KURA 0.61
- MLTX 0.61
- MACD
- KURA -0.01
- MLTX 1.64
- Stochastic Oscillator
- KURA 59.85
- MLTX 37.67
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.